How to talk to patients about JAK inhibitor safety | rheumatology.medicinematters.com

Register Login

Medicine Matters Rheumatology

JAVASCRIPT NEEDED

Please enable JavaScript on your browser, so that you can use all features of this website.

window.dataLayer = window.dataLayer || []; window.dataLayer.push({ 'event': 'track', 'eventCategory': 'flash_warning', 'eventAction': 'Javascript needed', 'eventLabel': 'Please enable JavaScript on your browser, so that you can use all features of this website.' });

06-07-2022 | JAK inhibitors | Ask the expert | Video

How to talk to patients about JAK inhibitor safety

Speaker: Victoria Ruffing

Following the results of the ORAL Surveillance trial, which demonstrated increased rates of adverse events in people taking JAK inhibitors, Victoria Ruffing provides guidance on how to talk to patients about the risks associated with these medications (6:42).

Related content

10-11-2021 | ACR 2021 | Conference coverage | News

ORAL Surveillance: Tofacitinib fails to show noninferiority vs TNF inhibitors for MACE, malignancy risk

11-08-2021 | JAK inhibitors | Feature | Article

JAK inhibitor safety: Distilling the evidence

Peter Nash discusses the latest evidence on the association between JAK inhibitors and the risk for VTE, MACE, and malignancy

11-11-2020 | ACR 2020 | Conference coverage | News

‘The Great Debate’: JAK inhibitors vs biologics following methotrexate failure in RA

02-09-2021 | JAK inhibitors | News

FDA requires boxed warning updates for JAK inhibitors

Version: 0.2059.0